The World Health Organization (WHO) has finally declared a Public Health Emergency of International Concern (PHEIC) in the Democratic Republic of the Congo on July 17 as a long overdue acknowledgement that the current Ebola outbreak remains uncontained and still poses a significant threat to global health"...

Boehringer Ingelheim and Bridge Biotherapeutics Inc. today announced that they are entering into a new collaboration and license agreement with the goal of developing Bridge Biotherapeutics’s autotaxin inhibitor BBT-877 for patients with fibrosing interstitial lung diseases, including IPF. BBT-877 is currently in Phase I clinical studies and is anticipated to enter Phase II testing within the next 12 months.

Both companies will initially focus"...

With the first reported case of Ebola emerging this week in Goma, a populous city in the eastern Democratic Republic of the Congo (DRC) next to the Rwandan city of Gisenyi, medical care providers and public health advocates from AIDS Healthcare Foundation (AHF) are speaking out loudly—declaring"...

ResMed Inc. (NYSE: RMD, ASX: RMD) announced today the successful pricing and closing of a private placement offering of $250,000,000 principal amount 3.24% senior notes due July 10, 2026, and $250,000,000 principal amount 3.45% senior notes due July 10, 2029.

Net proceeds from the offering will be approximately $498 million, after deducting estimated fees and expenses related to the offering. The net proceeds will be used to pay down current borrowings"...

CosmeSurge, one of the region’s most trusted brands for cosmetic and aesthetic procedures, has launched its 15th centre in the UAE and Oman. Located on the second floor of Bareen International Hospital in Mohammed Bin Zayed City, Abu Dhabi, the centre will provide innovative, high quality aesthetic and cosmetic dermatology and plastic surgery services for which the brand is renowned.

NMC Health’s Chief Operating Officer Michael Davis"...

SpeeDx Pty. Ltd. today announced ResistancePlus® MG has been cleared by Health Canada and is now available for sale across all Canadian provinces (not currently available in the U.S.). The molecular diagnostic test detects the sexually transmitted infection (STI) Mycoplasma genitalium, also known as Mgen, along with genetic markers linked to antibiotic resistance. This is the first commercially available test in Canada combining identification and therapeutic guidance information to support Resistance Guided Therapy for"...

Masimo (NASDAQ: MASI) announced today that in a study recently published in the Journal of Clinical Monitoring and Computing, researchers investigated the ability of Masimo ORi™ (Oxygen Reserve Index) to serve as a noninvasive indicator of the arterial partial pressure of oxygen (PaO2) during"...

The Ministry of Health (MoH)’s medical supplies department has received two of the latest hi-tech medical diagnostics systems, Assistant Undersecretary for HR and Services, Fatima A. Al Ahmed, said.

The BD100,000 precision ECHO device enables to detect children’s congenital heart disorders, cardiac rhythm and blood circulation. The BD 31,000 digital X-Ray device enables to detect bone fractures in the limbs, spinal column and joints.

Boehringer Ingelheim today announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL’s lead vaccine ATP128 is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this month. Boehringer Ingelheim plans to develop new therapies by combining assets from its cancer immunology portfolio with"...